PTHLH and prostate carcinoma: Overexpression of PTHrP (1–87) and PTHrP (1–173) in the non-invasive DU-145 human prostate cancer cell line converted these cells to an aggressive phenotype resulting in significantly greater bone tumor burden and mixed osteolytic/osteoblastic lesions following intrafemoral injection.